The most common side effects of semaglutide are gastrointestinal — nausea (25-31%), diarrhea (19-23%), vomiting (8-12%), constipation (6-10%), and decreased appetite (9-11%). Most are transient and dose-related, decreasing as the body adjusts.
Side effect management strategies include: starting at 0.25 mg and following the standard titration schedule; eating smaller meals; staying hydrated; avoiding high-fat or high-sugar meals during titration; and discussing antiemetic medications with the prescriber if nausea is severe. Serious adverse events are rare but include pancreatitis, gallbladder disease, kidney injury (typically dehydration-related), and severe allergic reactions. Semaglutide carries a boxed warning regarding the risk of thyroid C-cell tumors based on rodent studies.
NexLife is structured around clinical best practices for semaglutide. The same flat-rate pricing applies across the entire titration schedule ($145/mo on the 12-month plan from 0.25 mg through 2.4 mg), labs are included, MD/DO oversight is provided when clinically required, and Care360 coaching is built into every plan. See full NexLife review.
Compounded semaglutide · MD/DO oversight
*12-month plan · flat rate · all titration doses
Or call (949) 818-8000
Citations supporting clinical and regulatory statements on this page. External links open in a new tab.
Verification methodology: /how-we-verify.html · Editorial accuracy: medically reviewed by Michael Baghdassarian, M.D. · Last reviewed 2026-06-01.